Advertisement
Advertisement

ALVO

ALVO logo

Alvotech Ordinary Shares

3.23
USD
Sponsored
+0.09
+3.03%
Mar 26, 15:58 UTC -4
Closed
exchange

After-Market

3.24

+0.01
+0.15%

ALVO Earnings Reports

Positive Surprise Ratio

ALVO beat 5 of 10 last estimates.

50%

Next Report

Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$151.14M
/
$0.03
Implied change from Q4 25 (Revenue/ EPS)
-10.51%
/
-108.11%
Implied change from Q1 25 (Revenue/ EPS)
+13.81%
/
-91.43%

Alvotech Ordinary Shares earnings per share and revenue

On Mar 18, 2026, ALVO reported earnings of -0.37 USD per share (EPS) for Q4 25, missing the estimate of -0.04 USD, resulting in a -706.10% surprise. Revenue reached 168.90 million, compared to an expected 163.13 million, with a 3.54% difference. The market reacted with a -5.79% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 151.14 million USD, implying an decrease of -108.11% EPS, and decrease of -10.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q4 2025, Alvotech Ordinary Shares reported EPS of -$0.37, missing estimates by -706.1%, and revenue of $168.90M, 3.54% above expectations.
The stock price moved down -5.79%, changed from $3.80 before the earnings release to $3.58 the day after.
The next earning report is scheduled for May 06, 2026.
Based on 4 analysts, Alvotech Ordinary Shares is expected to report EPS of $0.03 and revenue of $151.14M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement